Antitumor activity of epigenetic immunomodulation combined with CTLA-4 blockade in syngeneic mouse models

OncoImmunology

Volumn 4, Issue 8, 2015, Pages

  Covre, A ^a   Coral, S ^a   Nicolay, H ^a   Parisi, G ^a   Fazio, C ^a,b   Colizzi, F ^c   Fratta, E ^c   Di Giacomo, A M ^a   Sigalotti, L ^c   Natali, P G ^d   Maio, M ^a  

^a UNIVERSITY HOSPITAL OF SIENA   (Italy)

^b UNIVERSITY OF SIENA   (Italy)

^c CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^d REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

cancer; CTLA 4; DNA methylation; immune responses; immunomodulation; immunotherapy

Indexed keywords

9H10 MONOCLONAL ANTIBODY; ANTINEOPLASTIC AGENT; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DECITABINE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; UNCLASSIFIED DRUG;

ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DEMETHYLATION; DNA EXTRACTION; DNA METHYLATION; FEMALE; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; IMMUNOMODULATION; MOUSE; NONHUMAN; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION; UPREGULATION;

EID: 84940473692     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2015.1019978     Document Type: Article

References (34)

1. L.Sigalotti, A.Covre, E.Fratta, G.Parisi, F.Colizzi, A.Rizzo, R.Danielli, H.J.Nicolay, S.Coral, M.Maio. Epigenetics of human cutaneous melanoma: setting the stage for new therapeutic strategies. J Transl Med 2010; 8:56; PMID:20540720; http://dx.doi.org/10.1186/1479-5876-8-56
2. L.Sigalotti, E.Fratta, S.Coral, M.Maio. Epigenetic drugs as immunomodulators for combination therapies in solid tumors. Pharmacol Ther 2014; 142(3):339-50; PMID:24384533; http://dx.doi.org/10.1016/j.pharmthera.2013.12.015
3. S.Coral, L.Sigalotti, M.Altomonte, A.Engelsberg, F.Colizzi, I.Cattarossi, E.Maraskovsky, E.Jager, B.Seliger, M.Maio. 5-aza-2′-deoxycytidine-induced expression of functional cancer testis antigens in human renal cell carcinoma: immunotherapeutic implications. Clin Cancer Res 2002; 8(8):2690-95; PMID:12171902
4. L.Sigalotti, E.Fratta, S.Coral, S.Tanzarella, R.Danielli, F.Colizzi, E.Fonsatti, C.Traversari, M.Altomonte, M.Maio. Intratumor heterogeneity of cancer/testis antigens expression in human cutaneous melanoma is methylation-regulated and functionally reverted by 5-aza-2′-deoxycytidine. Cancer Research. 2004; 64(24):9167-71; PMID:15604288; http://dx.doi.org/10.1158/0008-5472.CAN-04-1442
5. E.Fonsatti, H.J.Nicolay, L.Sigalotti, L.Calabro, L.Pezzani, F.Colizzi,, M.Altomonte, M.Guidoboni, F.M.Marincola, M.Maio. Functional up-regulation of human leukocyte antigen class I antigens expression by 5-aza-2′-deoxycytidine in cutaneous melanoma: immunotherapeutic implications. Clin Cancer Res 2007; 13(11):3333-38; PMID:17545540; http://dx.doi.org/10.1158/1078-0432.CCR-06-3091
6. S.Coral, A.Covre, H.J.Nicolay, G.Parisi, A.Rizzo, F.Colizzi, S.Dalla Santa, E.Fonsatti, E.Fratta, L.Sigalotti et al. Epigenetic remodelling of gene expression profiles of neoplastic and normal tissues: immunotherapeutic implications. Br J Cancer 2012; 107(7):1116-24; PMID:22910318; http://dx.doi.org/10.1038/bjc.2012.361
7. S.Coral, L.Sigalotti, A.Gasparollo, I.Cattarossi, A.Visintin, A.Cattelan, M.Altomonte, M.Maio. Prolonged upregulation of the expression of HLA class I antigens and costimulatory molecules on melanoma cells treated with 5-aza-2′-deoxycytidine (5-AZA-CdR). J Immunother 1999; 22(1):16-24; PMID:9924695; http://dx.doi.org/10.1097/00002371-199901000-00003
8. A.Covre, S.Coral, A.M.Di Giacomo, P.Taverna, M.Azab, M.Maio. Epigenetics meets immune checkpoints. Semin Oncol. Cancer Res 2015; 42(3):506-513;http://dx.doi.org/10.1053/j.seminoncol2015.02.00315
9. L.Calabro, R.Danielli, L.Sigalotti, M.Maio. Clinical studies with anti-CTLA-4 antibodies in non-melanoma indications. Semin Oncol 2010; 37(5):460-67; PMID:21074061; http://dx.doi.org/10.1053/j.seminoncol.2010.09.006
10. L.Calabro, M.Maio. Immune checkpoint blockade in malignant mesothelioma: A novel therapeutic strategy against a deadly disease? Oncoimmunology 2014; 3(1):e27482; PMID:24734215; http://dx.doi.org/10.4161/onci.27482
11. M.Maio, A.M.Di Giacomo, C.Robert, A.M.Eggermont. Update on the role of ipilimumab in melanoma and first data on new combination therapies. Curr Opin Oncol 2013; 25(2):166-72; PMID:23299197; http://dx.doi.org/10.1097/CCO.0b013e32835dae4f
12. J.D.Wolchok, J.S.Weber, M.Maio, B.Neyns, K.Harmankaya, K.Chin, L.Cykowski,, V.de Pril, R.Humphrey, C.Lebbe. Four-year survival rates for patients with metastatic melanoma who received ipilimumab in phase II clinical trials. Ann Oncol 2013; 24(8):2174-80; PMID:23666915; http://dx.doi.org/10.1093/annonc/mdt161
13. A.M.Di Giacomo, L.Calabro, R.Danielli, E.Fonsatti, E.Bertocci, I.Pesce, C.Fazio, O.Cutaia, D.Giannarelli, C.Miracco et al. Long-term survival and immunological parameters in metastatic melanoma patients who responded to ipilimumab 10 mg/kg within an expanded access programme. Cancer Immunol Immunother 2013; 62(6):1021-28; PMID:23591982; http://dx.doi.org/10.1007/s00262-013-1418-6
14. F.S.Hodi, S.J.O'Day, D.F.McDermott, R.W.Weber, J.A.Sosman, J.B.Haanen, R.Gonzalez, C.Robert, D.Schadendorf, J.C.Hassel et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363(8):711-23; PMID:20525992; http://dx.doi.org/10.1056/NEJMoa1003466
15. D.M.Pardoll. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012; 12(4):252-64; PMID:22437870; http://dx.doi.org/10.1038/nrc3239
16. J.Weber. Immune checkpoint proteins: a new therapeutic paradigm for cancer-preclinical background: CTLA-4 and PD-1 blockade. Semin Oncol 2010; 37(5):430-39; PMID:21074057; http://dx.doi.org/10.1053/j.seminoncol.2010.09.005
17. M.A.Curran, M.Kim, W.Montalvo, A.Al-Shamkhani, J.P.Allison. Combination CTLA-4 blockade and 4-1BB activation enhances tumor rejection by increasing T-cell infiltration, proliferation, and cytokine production. PLoS One 2011; 6(4):e19499; PMID:21559358; http://dx.doi.org/10.1371/journal.pone.0019499
18. A.Van Elsas, A.A.Hurwitz, J.P.Allison. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J Exp Med 1999; 190(3):355-66; PMID:10430624; http://dx.doi.org/10.1084/jem.190.3.355
19. G.K.Pennock, W.Waterfield, J.D.Wolchok. Patient responses to ipilimumab, a novel immunopotentiator for metastatic melanoma: how different are these from conventional treatment responses? Am J Clin Oncol 2012; 35(6):606-11; PMID:21336089; http://dx.doi.org/10.1097/COC.0b013e318209cda9
20. J.D.Wolchok, A.Hoos, S.O'Day, J.S.Weber, O.Hamid, C.Lebbe, M.Maio, M.Binder, O.Bohnsack, G.Nichol et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 2009; 15(23):7412-20; PMID:19934295; http://dx.doi.org/10.1158/1078-0432.CCR-09-1624
21. A.Anichini, F.G.de Braud, R.Montarini, I.Bersani, G.Tragni, L.de Cecco, S.Canevari, L.Di guardo, L.Pilla, M.Del Vecchio. Loss of HLA molecules as melanoma resistance mechanism in immune checkpoint blockade therapy. Mol Cancer Ther 2013; 12:A89; http://dx.doi.org/10.1158/1535-7163.TARG-13-A89
22. M.A.Curran, W.Montalvo, H.Yagita, J.P.Allison. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci U S A 2010; 107(9):4275-80; PMID:20160101; http://dx.doi.org/10.1073/pnas.0915174107
23. P.Shrikant, A.Khoruts, M.F.Mescher. CTLA-4 blockade reverses CD8+ T cell tolerance to tumor by a CD4+ T cell- and IL-2-dependent mechanism. Immunity 1999; 11(4):483-93; PMID:10549630; http://dx.doi.org/10.1016/S1074-7613(00)80123-5
24. A.Tarhini. Immune-mediated adverse events associated with ipilimumab ctla-4 blockade therapy: the underlying mechanisms and clinical management. Scientifica (Cairo) 2013:857519; PMID:24278787; http://dx.doi.org/10.1155/2013/857519
25. J.S.Weber, K.C.Kahler, A.Hauschild. Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol 2012; 30(21):2691-97; PMID:22614989; http://dx.doi.org/10.1200/JCO.2012.41.6750
26. J.Liu, S.J.Blake, M.J.Smyth, M.W.L.Teng. Improved mouse models to assess tumour immunity and irAEs after combination cancer immunotherapies. Clin Transl Immunol 2014; 3:e22; PMID:25505970; http://dx.doi.org/10.1038/cti.2014.18
27. P.Nanni, C.De Giovanni, P.L.Lollini, G.Nicoletti, G.Prodi. TS/A: a new metastasizing cell line from a BALB/c spontaneous mammary adenocarcinoma. Clin Exp Metastasis 1983; 1(4):373-80; PMID:6546207; http://dx.doi.org/10.1007/BF00121199
28. M.R.Davis, L.S.Manning, D.Whitaker, M.J.Garlepp, B.W.Robinson. Establishment of a murine model of malignant mesothelioma. Int J Cancer 1992; 52(6):881-86; PMID:1459729; http://dx.doi.org/10.1002/ijc.2910520609
29. P.Workman, E.O.Aboagye, F.Balkwill, A.Balmain, G.Bruder, D.J.Chaplin, J.A.Double, J.Everitt, D.A.Farningham, M.J.Glennie et al. Guidelines for the welfare and use of animals in cancer research. Br J Cancer 2010; 102(11):1555-77; PMID:20502460; http://dx.doi.org/10.1038/sj.bjc.6605642
30. Z.S.Guo, J.A.Hong, K.R.Irvine, G.A.Chen, P.J.Spiess, Y.Liu, G.Zeng, J.R.Wunderlich, D.M.Nguyen, N.P.Restifo et al. De novo induction of a cancer/testis antigen by 5-aza-2′-deoxycytidine augments adoptive immunotherapy in a murine tumor model. Cancer Res 2006; 66(2):1105-13; PMID:16424047; http://dx.doi.org/10.1158/0008-5472.CAN-05-3020
31. E.De Plaen, O.De Backer, D.Arnaud, B.Bonjean, P.Chomez, V.Martelange, P.Avner, P.Baldacci, C.Babinet, S.Y.Hwang, et al. A new family of mouse genes homologous to the human MAGE genes. Genomics 1999; 55(2):176-84; PMID:9933564; http://dx.doi.org/10.1006/geno.1998.5638
32. L.C.Li, R.Dahiya. MethPrimer: designing primers for methylation PCRs. Bioinformatics 2002; 18(11):1427-31; PMID:12424112; http://dx.doi.org/10.1093/bioinformatics/18.11.1427
33. K.Ozato, D.H.Sachs. Monoclonal antibodies to mouse MHC antigens. III. Hybridoma antibodies reacting to antigens of the H-2b haplotype reveal genetic control of isotype expression. J Immunol 1981; 126(1):317-21; PMID:6935293
34. S.T.Kuhns, L.R.Pease. A region of conformational variability outside the peptide-binding site of a class I MHC molecule. J Immunol 1998; 161(12):6745-50; PMID:9862704